Plus Therapeutics Discloses Substantial 2025 Executive Compensation, CEO Totaling $5.56M
PSTV sits 70% above its 52-week low of $0.163.
Summary
Plus Therapeutics disclosed its 2025 executive compensation, revealing a significant increase for its CEO and CFO, with the CEO's total compensation reaching $5.56 million.
Key Events · Executive and Board Changes · PSTV
-
Executive Compensation Approved
The Compensation Committee approved discretionary cash bonuses for Named Executive Officers for Fiscal Year 2025 on February 9, 2026.
-
CEO Compensation Details
President and CEO Marc H. Hedrick's total compensation for 2025 was $5,566,732, a substantial increase from $1,260,285 in 2024, primarily driven by option and restricted stock awards.
-
CFO Compensation Details
CFO Andrew Sims' total compensation for 2025 was $1,631,279, up from $621,116 in 2024.
-
Context of Prior Disclosure
This disclosure finalizes compensation figures that were previously noted as undetermined in the company's S-1 registration statement filed on January 9, 2026.
Analysis · PSTV · Industrial Applications And Services
This 8-K filing reveals the final 2025 compensation for Plus Therapeutics' Named Executive Officers, which was previously pending as noted in the S-1 registration statement filed on January 9, 2026. The disclosed figures show a substantial increase in total compensation for both the CEO and CFO, with the CEO's package reaching $5.56 million. This significant compensation, particularly the large equity awards, comes shortly after the company completed a dilutive public offering in mid-January, raising approximately $13.3 million in net proceeds. Investors may scrutinize the magnitude of executive compensation relative to the company's market capitalization and recent capital-raising activities, potentially raising concerns about shareholder value and capital allocation.
At the time of this filing, PSTV was trading at $0.28 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $49.1M. The 52-week trading range was $0.16 to $2.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.